Abraham N. Ceesay's most recent trade in Pacira BioSciences Inc was a trade of 11,279 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pacira BioSciences Inc | Abraham N. Ceesay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 11,279 | 11,279 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Abraham N. Ceesay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 6,163 | 11,393 (0%) | 0% | 0 | Common Stock | |
| Rapport Therapeutics Inc. | Abraham N. Ceesay | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 428,000 | 428,000 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Abraham N. Ceesay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,179 | 12,179 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Abraham N. Ceesay | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 5,230 | 5,230 (0%) | 0% | 0 | Common Stock | |
| Rapport Therapeutics Inc. | Abraham N. Ceesay | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 530,647 | 530,647 | - | - | Stock Option (Right to Buy) |